Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd (APLLTD) last traded at ₹803, a market capitalisation of ₹15,786 crore, on a P/E of 21.1. Over the past 52 weeks the stock has ranged between ₹635 and ₹998. Alembic Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹2,150 crore and net profit of ₹172 crore. Figures are as of 25 Aug 2026 and are not real time.
Alembic Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Alembic Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,150 cr, up 25.7% from ₹1,711 cr a year earlier. Net profit was ₹172 cr, up 11.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 |
| Expenses | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 |
| Operating profit | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 |
| OPM % | 15% | 15% | 15% | 16% | 17% | 16% | 12% | 15% |
| Other income | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 |
| Interest | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| Profit before tax | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 |
| Tax % | 15% | 23% | 18% | 19% | 18% | 18% | -70% | 22% |
| Net profit | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| EPS (₹) | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alembic Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 | 7,784 |
| Operating profit | 1,480 | 874 | 682 | 932 | 1,008 | 1,121 | 1,167 |
| OPM % | 27% | 16% | 12% | 15% | 15% | 15% | 15% |
| Net profit | 1,146 | 521 | 342 | 616 | 582 | 671 | 690 |
| EPS (₹) | 58.33 | 26.50 | 17.40 | 31.33 | 29.68 | 34.33 | 35.27 |
TTM is the trailing twelve months to the most recent quarter.
Alembic Pharmaceuticals Ltd growth and returns
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 9%
- TTM
- 14%
- 10 Years
- 0%
- 5 Years
- -9%
- 3 Years
- 28%
- TTM
- 26%
- 10 Years
- 3%
- 5 Years
- 2%
- 3 Years
- 3%
- 1 Year
- -16%
- 10 Years
- 16%
- 5 Years
- 11%
- 3 Years
- 13%
- Last Year
- 13%
Alembic Pharmaceuticals Ltd shareholding pattern
Promoters held 69.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.17% and DIIs 15.93%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 69.61% | 69.61% | 69.67% | 69.68% | 69.74% | 69.74% | 69.74% | 69.87% |
| FIIs | 3.94% | 4.17% | 3.94% | 3.96% | 4.04% | 4.23% | 4.26% | 4.17% |
| DIIs | 16.05% | 16.05% | 16.43% | 16.46% | 16.30% | 16.17% | 16.17% | 15.93% |
| Public | 10.38% | 10.17% | 9.96% | 9.91% | 9.92% | 9.84% | 9.83% | 10.00% |
| No. of shareholders | 91,429 | 93,944 | 91,336 | 89,013 | 89,969 | 87,000 | 86,432 | 86,796 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Alembic Pharmaceuticals Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has fulfilled its regulatory obligation under Regulation 30 of…
Read the full analysis - Intimation regarding Appointment of Company Secretary of the Company.Company Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has announced the appointment of Mr. Chirag Shukla as the…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has published a notice in newspapers regarding the disclosure of…
Read the full analysis - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has formally notified the stock exchanges regarding the…
Read the full analysis - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Alembic Pharmaceuticals reported a strong Q1 FY27 with consolidated revenue growing 26%…
Read the full analysis - Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAGM/EGMlow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has successfully concluded its 16th Annual General…
Read the full analysis - Shareholder Meeting / Postal Ballot-Outcome of AGMAGM/EGMlow impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has successfully concluded its 16th Annual General…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has published a routine newspaper advertisement in compliance…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeCompany Updatelow impact
Cruxal's analysis: Alembic Pharmaceuticals has filed the audio recording of its recent investor/analyst…
Read the full analysis - Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Company Updatemedium impact
- Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseCompany Updatehigh impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has reported a robust performance for Q1 FY27, with…
Read the full analysis - Announcement under Regulation 30 (LODR)-Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has announced impressive unaudited financial results for…
Read the full analysis - Board Meeting Outcome for Outcome Of Board MeetingBoard Meetinghigh impact
Cruxal's analysis: Alembic Pharmaceuticals Limited has announced robust consolidated financial results for…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Alembic Pharmaceuticals Ltd
Cruxal reads every Alembic Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.